Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative anti-Factor Xa activity between standard and Japanese rivaroxaban doses in Thai NVAF patients
TCTR20181104002Completed
- Sponsor
- Faculty of Medicine, Chiang Mai University
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Faculty of Medicine, Chiang Mai University. Primary endpoint: anti-Factor Xa activity comparison. Started Jun 2018; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on TCTR20181104002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20181104002.